

APPLICATION OF RECOMBINANT SMR-DOMAIN CONTAINING PROTEIN OF *ANGIOSTRONGYLUS CANTONENSIS* IN IMMUNOBLOT DIAGNOSIS OF HUMAN ANGIOSTRONGYLIASIS

Apichat Vitta¹, Timothy P Yoshino², Thareerat Kalambaheti³, Chalit Komalamisra¹, Jitra Waikagul¹, Jiraporn Ruangsittichai⁴ and Paron Dekumyoy¹

¹Department of Helminthology, ³Department of Microbiology and Immunology, ⁴Department of Medical Entomology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; ²Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, WI, USA

Abstract. The aim of this study was to find novel proteins expressed from an *Angiostrongylus cantonensis* adult female worm cDNA library for serodiagnosis of angiostrongyliasis. An immuno-dominant clone, fAC22, was identified by immunoscreening with pooled positive sera from proven angiostrongyliasis patients. The clone contained an open reading frame of 2,136 bp encoding a 80.5 kDa protein with a predicted isoelectric point of 5.8. The deduced amino acid sequence (712 amino acids) contained the conserved domain of Small mutS related (Smr) superfamily protein, with similarity with the Smr domain protein of *Brugia malayi*. The fusion His-tagged 81 kDa recombinant protein expressed as inclusion body in *Escherichia coli* was solubilized and purified by Ni-affinity chromatography for use in immunoblot analysis. Its sensitivity, specificity, positive and negative predictive values in immunodiagnostic test was 93.5, 91.5, 79.0 and 97.5%, respectively. Although some cross-reactivity of the antigen was observed among gnathostomiasis, bancroftian filariasis, ascariasis, echinococcosis, paragonimiasis and opisthorchiasis, sera from 14 other infections were all negative. These data indicate its possible application in immunodiagnosis of clinically suspected angiostrongyliasis.

Key words: *Angiostrongylus cantonensis*, eosinophilic meningitis, recombinant fusion protein, immunodiagnosis

INTRODUCTION

Human angiostrongyliasis is a food-borne parasitic zoonosis caused by infec-

tion with the larval stage of the rat lung-worm *Angiostrongylus cantonensis*. Among human helminthic infections, *A. cantonensis* is known to be the primary cause of eosinophilic meningitis or meningoencephalitis. In the early 2000s, 3 outbreaks of the disease were reported, from Taiwan (Tsai *et al*, 2001), the Caribbean (Slom *et al*, 2002) and China (Chen *et al*, 2005). Recently, at least 2,827 cases of the disease have been documented worldwide and over half of

Correspondence: Paron Dekumyoy, Department of Helminthology, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Bangkok 10400, Thailand.

Tel: 66 (0) 2354 9100 to 4 ext 9180-1; Fax: 66 (0) 2643 5600

E-mail: tmpdk@mahidol.ac.th

these cases (1,337) were reported from Thailand (Wang *et al*, 2008). Moreover, this parasite can occasionally be the cause of ocular angiostrongyliasis (Sawanyawisuth *et al*, 2007; Sinawat *et al*, 2008).

A definitive diagnosis of angiostrongyliasis is made by finding the immature worms in the eyes or cerebrospinal fluid (CSF) of patients. However, recovery of worms from human patients rarely occurs. Diagnosis of the disease is commonly made by the combination of clinical symptoms, laboratory findings and history of eating intermediate or paratenic hosts. To assist in the diagnosis of this disease, several serological tests have been reported, such as enzyme-linked immunosorbent assay (ELISA) and immunoblot (Chen, 1986; Yen and Chen, 1991; Akao *et al*, 1992; Eamsobhana *et al*, 1995, 1997; Nuamtanong, 1996; Maleewong *et al*, 2001). In the early studies, detection of antibody against *A. cantonensis* was done by using different kinds of antigens, such as crude or partially purified adult worm antigens (Welch *et al*, 1980; Chen, 1986), young adult worm antigens (Cross and Chi, 1982; Yen and Chen, 1991) or female adult antigens (Yen and Chen, 1991; Nuamtanong, 1996). Results obtained using these antigen preparations, however, have been unsatisfactory because of cross-reactivity with antibodies from other parasitic infections.

A group of the native antigens, including purified proteins of 29 kDa, 31 kDa and 32 kDa, from *A. cantonensis* have been widely used in IgG- and IgG₁₋₄-immunoblotting tests for diagnosis of human angiostrongyliasis (Nuamtanong, 1996; Maleewong *et al*, 2001; Intapan *et al*, 2003; Eamsobhana *et al*, 2004). All native antigens are derived by extraction of *Angiostrongylus* worms, all stages of which are maintained in the laboratory by cycling through snail

hosts and experimental rats. Maintaining the parasite life cycle is laborious and time-consuming, and requires the slaughtering of experimental animals to obtain antigen materials. In addition, such antigens exhibit considerable variability in sensitivity and specificity in diagnostic tests. Therefore, novel antigens are still needed for more specific serodiagnosis of angiostrongyliasis.

In the present study, a molecular cloning approach was used to express recombinant antigenic fusion protein derived from cDNA of adult female worms of *A. cantonensis*. By immunoscreening, a clone encoding an 80.5 kDa protein was analyzed for its DNA sequence and antigenic property for detection of angiostrongyliasis.

MATERIALS AND METHODS

Experimental production of *A. cantonensis*

A. cantonensis worms were experimentally maintained in the rat definitive host, *Rattus norvegicus*, in the Department of Helminthology, Faculty of Tropical Medicine, Mahidol University, Thailand. An intermediate host, the freshwater snail, *Biomphalaria glabrata*, was infected with freshly isolated first-stage larvae from the rat feces. After 6 weeks of infection, the third stage (L3) larvae were harvested by HCl-pepsin digestion of chopped snails and isolated by the Baerman technique (Nuamtanong, 1996). Sixteen female rats, 6 weeks old, were used as the definitive host. They were individually infected with 30 L3 larvae by stomach intubation under light anesthesia. After 2-4 months of infection, fecal samples were examined for first stage larvae. Infected rats were then killed by an overdose of ether. Adult worms were harvested from the pulmonary arteries and right side of the heart. The worms

were washed with sterile 0.85% NaCl and used for extraction of total RNA. This study was approved by the animal care and use committee, Faculty of Tropical Medicine, Mahidol University (Project No. FTM-ACUC 009/2007).

Extraction of total RNA and purification of mRNA

Thirty freshly harvested female *A. cantonensis* (approximately, 100 mg wet weight) were homogenized in a glass tissue grinder. Total RNA was extracted with TRIzol[®] reagent according to the manufacturer's instructions (Invitrogen-Life Technologies, Carlsbad, CA). Messenger RNA (mRNA) was purified from 3 mg of total RNA using Oligotex mRNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. To concentrate the mRNA by precipitation, 1/10 volume of 3 M sodium acetate (pH 5.2) and 2.5 volumes of absolute ethanol were added to mRNA solution. The tube was kept at -20°C overnight and then centrifuged at 12,000g for 30 minutes at 4°C. The pellet was washed with 75% (v/v) ethanol in RNase-free water, air-dried at room temperature for 10-15 minutes, and finally dissolved in 40 µl of RNase-free water and used for constructing cDNA library.

Construction and immunoscreening of cDNA library

A. cantonensis cDNA library was constructed using ZAP Express[®] cDNA Synthesis kit according to the manufacturer's instructions (Stratagene, La Jolla, CA). The phage titer was determined in order to plate the correct number of plaque forming units (PFUs) per plate before immunoscreening. The bacterial host strain, *E. coli* XL-1 Blue MRF/, was mixed with phage stock and incubated at 37°C for 15 minutes. Then 3 ml of NZY top agarose, 15 µl of 0.5 M IPTG (in water) and

50 µl of X-Gal (250 mg/ml in DMF) were added to the mixture. After mixing well, the solution was immediately poured onto pre-warmed NZY agar plates. The plates were incubated in an inverted position at 37°C overnight to develop the plaque color. Plaques were counted to determine the integrity of the library (PFU/ml).

In order to isolate and identify the antigenic clones, approximately 200,000 plaques from the amplified libraries were screened using pooled sera from 5 angiostrongyliasis patients. The pooled sera were pre-treated with *E. coli* phage lysate (Stratagene, La Jolla, CA) to eliminate any background cross-reactivity and false positive reactivity from antibodies against *E. coli*. Plaques were grown on NZY agar for 4 hours at 42°C before they were overlaid with nitrocellulose membranes (Schleicher and Schuell) impregnated with 10 mM IPTG. After incubation at 37°C for 4 hours, membranes were incubated with 1% bovine serum albumin (BSA) at 4°C overnight. They were incubated with the pre-adsorbed pooled positive serum (diluted 1:2,000 with BSA solution) at 4°C overnight, followed by incubation in alkaline phosphatase (AP)-conjugated goat anti-human IgG (Sigma, St Louis, MO) at a dilution of 1:20,000 for 2 hours at room temperature before the color reaction was developed with nitroblue tetrazolium chloride (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). Positive purple plaques were removed from the master plate and subjected to secondary screening at a lower density as described above. Tertiary screening was performed to ensure clonality.

Preparation of plasmid DNA and estimation of cDNA insert size

Single-clone excision protocol was performed according to the manufacture's

instructions (Stratagene). Plasmids were purified using QIAprep Spin Miniprep kit according to the manufacturer's instructions (Qiagen, Valencia, CA). The size of cDNA insert was determined by double digestion with *KpnI* and *SacI* (Promega, Madison, WI), followed by visualization of the digested plasmids in 1% agarose gel and comparison with DNA molecular weight standard markers.

Sequencing and sequence analysis

Plasmid DNA sequencing of the selected clones was performed by the Biotechnology Center at the University of Wisconsin-Madison, USA. The nucleotide sequences were converted to amino acid sequences using BioEdit version 5.0.9 (www.mbio.ncsu.edu/BioEdit/BioEdit.html). The deduced amino acid sequences were subjected to a homology search against a non-redundant protein database using BLASTP program of the National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov>). ClustalW program was used to align between deduced amino acid sequences.

Expression and purification of recombinant protein

The cDNA insert of the clone, fAC22, was subcloned into pET-46 Ek/LIC expression vector according to the Ek/LIC cloning kit (Novagen, Madison, WI). Open reading frame (ORF) of fAC22 was amplified by PCR with forward primer 5'-GACGACGACAAGATGCAACAGTATGCTTTTCATGC-3' and reward primer 5'-GAGGAGAAGCCCGGTTATTTGCATTGAACCACAACCTTC-3' [The start codon (ATG) and antisense stop codon (TTA) are indicated in bold]. PCR parameters were as follows: initial heating at 95°C for 3 minutes, then 35 cycles of 30 seconds at 95°C, 45 seconds at 55°C, and 2 minutes at 72°C; and a final step at 72°C for 10 minutes. The

PCR product was electrophoresed and gel-purified according to the Qiagen gel extraction kit (Qiagen, Valencia, CA), and then it was transfected into *E. coli* strain BL21(DE3). For induction of the His6-tagged protein, transformants were grown in LB-broth containing 100 µg/ml of ampicillin at 37°C until the OD₆₀₀ reached 0.4-0.6, followed by induction of expression with 1 mM IPTG for 4 hours. Bacterial cells were sedimented by centrifugation at 8,000g for 10 minutes and then resuspended in 5 ml of LEW lysis buffer (50 mM NaH₂PO₄ and 300 mM NaCl) and 2 ml of BugBuster[®] Master Mix (Novagen, Madison, WI). Cells were lysed by sonication on ice 6 times for 10 seconds with 10 seconds pauses (Sonicator[®] ultrasonical processor XL 2020) followed by centrifugation at 8,000g for 20 minutes at 4°C. Recombinant fusion protein was resuspended in 5 ml of denaturant buffer (50 mM NaH₂PO₄, 300 mM NaCl, 8 M urea, pH 8) followed by sonication as described above. After centrifugation at 10,000g for 30 minutes at 4°C, soluble recombinant His6 fusion protein was purified using Ni-NTA chromatography according to the manufacturer's instructions (Ni-NTA ProBond, Invitrogen, CA).

SDS-PAGE and immuno-characterization of recombinant fusion protein

The purified His6 fusion protein was electrophoresed in a 13% SDS-PAGE and then transferred to a nitrocellulose membrane. Membrane was incubated with 3% skim milk BSA in PBS-Tween20 (PBS-T) followed by incubation in a 1:50 dilution of pooled positive or pooled negative sera at 4°C overnight with rocking platform. Membrane was washed, incubated with anti-human IgG (Southern Biotech, Birmingham, AL) conjugated with horseradish peroxidase (HRP) at a dilution of 1:1000

(in PBS-T) for 2 hours at room temperature. Membrane was washed 3 times with PBS-T before color development with 2,6-dichlorophenol indophenol/H₂O₂ substrate. The reaction was terminated by placing in distilled water.

Application of purified fusion recombinant protein for serodiagnosis

All serum samples were supplied by Immunodiagnostic Unit for Helminthic Infections, Department of Helminthology, Faculty of Tropical Medicine, Mahidol University. Serum samples were divided into 3 groups: (i) normal group, which included samples from people ($n = 31$) proven to be parasite-free using fecal examinations comprising of a simple smear method, formalin-detergent floatation technique and the Kato technique (Garcia, 2007); (ii) Second group, which included samples from either confirmed angiostrongyliasis positive patients (worm-positive) ($n = 4$) or from patients showing clinical criteria ($n = 57$) and had consumed snail intermediate hosts or paratenic hosts and were immunoblot positive for 31 kDa band; (iii) Third group, which consisted of samples from patients with other parasitic infections ($n = 144$), including gnathostomiasis, strongyloidiasis, hookworm infection, trichinellosis, toxocariasis, ascariasis, trichuriasis, bancroftian filariasis, brugian filariasis, dirofilariasis, neurocysticercosis, taeniasis, echinococcosis, sparganosis, hymenolepiasis, haplorchiasis, paragonimiasis, opisthorchiasis, schistosomiasis and fascioliasis.

Purified recombinant fusion protein was electrophoresed in a single-well 13% SDS-PAGE slab gel and electrotransferred to a nitrocellulose membrane. After blocking nonspecific binding sites with 3% skim milk for 1 hour, the membrane was cut into ~3 mm wide strips. Each strip was incu-

bated with individual human serum samples (diluted 1:50 in PBS-T containing 0.02% NaN₃) overnight at room temperature. After 3 washes with PBS-T, the strips were incubated for 2 hours in 1:1,000 diluted goat anti-human IgG conjugated with HRP (Southern Biotech, Birmingham, AL). After 3 washes with PBS-T, positive reactions were developed with 2,6-dichlorophenol indophenol/H₂O₂ substrate. Reaction was terminated by placing in distilled water.

Data analysis

In order to evaluate the 81-kDa recombinant fusion protein for serodiagnosis based on immunoblotting, parameters of sensitivity, specificity, and positive and negative predictive values were calculated as previously described (Galen, 1980).

RESULTS

Construction and immunoscreening of *A. cantonensis* cDNA library

Total RNA was observed to be intact by electrophoresis in 1.2% agarose/ethidium bromide gel as evidenced by a single stained smear ranging from 200 to 6,000 bp in size. From this RNA preparation a primary *A. cantonensis* cDNA library was successfully constructed with a titer of 4.03×10^5 PFU/ml and 97.3% of the library producing white plaques. The titer of the amplified library was 3.63×10^8 PFU/ml. In a primary immunoscreening, approximately 200,000 plaques were screened with pre-absorbed pooled positive human serum. This yielded 67 positive clones. After secondary and tertiary screenings, 44 positive clones were identified as indicated by strong positive antibody staining (purple coloration). One clone, named fAC22, was subjected to *in vivo* excision phagemid for further sequence analysis.

Analysis of the cDNA insert and amino acid sequence

The cDNA insert was removed by an *in vivo* excision protocol. The pBK-CMV phagemid was isolated from *E. coli* XL0LR strain. The plasmid was double digested with *Kpn*I and *Sac*I restriction enzymes and following electrophoresis, the insert cDNA from clone fAC22 was estimated to be ~3.0 kbp in size (Fig 1).

The entire cDNA sequence (2,736 bp) and deduced amino acid sequences of clone fAC22 were determined (Fig 2). It consisted of a 57 bp 5' untranslated region (5' UTR), ORF of 2,136 bp encoding 712 amino acids, 516 bp of 3' UTR and 24 bp of poly(A). A putative polyadenylation signal sequence (ATTAAA) was located 18 bp upstream of the poly(A) sequence. The predicted molecular weight and isoelectric point was 80.5 kDa and 5.8, respectively. After a BLASTP search, a putative Small MutS related (Smr) domain-containing peptide segment was found at the N-terminus of the protein. Its amino acid sequence exhibited 24% similarity/homology to the Smr-domain containing protein of the nematode parasite, *Brugia malayi* (accession no. XP_001893874) (Fig 3). In addition, the deduced amino acid sequence showed similarity (24-36% homology) to several other proteins containing Smr domains, including *Aspergillus flavus* (accession no. EED56380), *Talaromyces stipitatus* (accession no. EED23317), *Penicillium marneffei* (accession no. XP_002144766) and *Neosartorya fischeri* (accession no. XP_001257903).

Expression, purification and immunocharacterization of the recombinant fusion protein

The fAC22 ORF was amplified by PCR and cloned into pET-46 Ek/LIC expression vector. The fAC22 recombinant protein




Fig 1—Double digestion of recombinant pBK-CMV phagemid (clone fAC22) by *Kpn*I and *Sac*I restriction enzymes. Lane M shows DNA marker. Lane 1 shows insertion cDNA (2,836 bp) excised from pBK-CMV phagemid (3,884 bp).

fused with a His6-tag was expressed in *E. coli* [BL21(DE3) strain] after induction with 1mM IPTG. Its size on 13% SDS-PAGE gel stained with Coomassie brilliant blue was approximately 81 kDa and the incubation period yielding optimum expression was 3 hours (Fig 4A). The recombinant His6-tagged fusion protein was heterologously expressed in an insoluble form, and therefore had to be purified under denaturing conditions. Purified recombinant protein was eluted from the Ni-NTA column with 100 mM imidazole as indicated by a single band 13% SDS-PAGE gel stained with Coomassie brilliant blue (Fig 4B) and silver (Fig 4C). The antigenic property of this fusion protein was confirmed by its strong reactivity with pooled positive serum (Fig 4D) compared to the pooled negative serum control (Fig 4E).

IMMUNOBLOT DIAGNOSIS OF ANGIOSTRONGYLIASIS

1	ggc acg agg ggc atc aaa aca gta gtc gtg gac aac acc aat att	45
46	ttc atc cat cac atg caa cag tat gct ttt cat gct gtt aga tac	90
	M Q Q Y A F H A V R Y	11
91	tgc tac gaa att ttt gtc gtg gaa cca gag acc acg tgg aaa tac	135
12	C Y E I F V V E P E T T W K Y	26
136	aca gtt aga gag tgc ttc aga cgc aac ata cat ggg ata gaa ata	180
27	T V R E C F R R N I H G I E I	41
181	tgg aaa att gat tgc atg atg cag tgc ttg ctt gat caa ggg cga	225
42	W K I D S M M Q S L L D Q G R	56
226	ccg act tta tct tgt ttg gta ggt gga gac cgt gaa att agg ttg	270
57	P T L S C L V G G D R E I R L	71
271	gtg cca cca ctt gaa ttt tgc gaa aaa gag cac gac acg gaa ttt	315
72	V P P L E F S E K E H D T E F	86
316	cac tgt ttg aag cta aga agt ctt gtg cta gat act tca cca aat	360
87	H C L K L R S L V L D T S P N	101
361	cgc gat gaa atc ttg cat tta aag gat gat gat ggc cct tct cca	405
102	R D E I L H L K D D D G P S P	116
406	gag gtc tct att gct gat cct cct ctt gag ctt cct tat ccg aat	450
117	E V S I A D P P L E L P Y P N	131
451	gct gca gtt gac cgt tgc tca ttt ctg ctg cct tca gtt gcg ccg	495
132	A A V D R S S F L L P S V A P	146
496	act cct gct gct ttt tgc tta gct gtc gat cgt cgt tca cat att	540
147	T P A A F S L A V D R R S H I	161
541	aga ata tta gaa gtt cga gaa gta gcg act caa act aat gag atc	585
162	R I L E V R E V A T Q T N E I	176
586	gtc gta aca tta gtc tgt gct ggc gtc tat tgt ccg ttt gat gac	630
177	V V T L V C A G V Y C P F D D	191
631	gtt tca gaa ggt gtt cca cat agc gtg gaa ata tca aaa gag ttg	675
192	V S E G V P H S V E I S K E L	206
676	aag tca caa atg aag gat cgt gta gtc aga atg gag aac att cca	720
207	K S Q M K D R V V R M E N I P	221
721	cag ttt tct gag ttg gac gtg ttg gtt gca gtc ttt ccg tac gag	765
222	Q F S E L D V L V A V F P Y E	236
766	gag ctt ggg aac ctt tct cat tat tat cag atg ctg ggt ttg gaa	810
237	E L G N L S H Y Y Q M L G L E	251
811	gaa tgc atc agg tta ttc gtg gaa ttg gga gct tat gta gac tgg	855
252	E C I R L F V E L G A Y V D W	266
856	atg gca cag gtt acg gag aaa ccg ttc gta gag gag ctt gca gca	900
267	M A Q V T E K P F V E E L A A	281
901	tct gaa ctc agt ggt act cta ctt cac gct cca gta ccc agg act	945
282	S E L S G T L L H A P V P R T	296
946	gac tgg gaa aga ata gca gaa cag gag agt atg aaa gaa tat gtg	990
297	D W E R I A E Q E S M K E Y V	311
991	gta act gag cca gtt tat gaa gtt ggt tct tca cga agt gtg gat	1035
312	V T E P V Y E V G S S R S V D	326

SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH

1036	tat	tcg	gga	aat	gag	ata	aca	gta	aca	ctt	ggc	gtt	gat	ttg	ctg	1080
327	Y	S	G	N	E	I	T	V	T	L	G	V	D	L	L	341
1081	caa	aag	atc	agt	tta	ttg	ttt	ggt	gaa	gga	atc	att	gtt	gaa	gaa	1125
342	Q	K	I	S	L	L	F	G	E	G	I	I	V	E	E	356
1126	gaa	tgt	agt	gta	cgt	ttg	cca	ctc	tgg	ctt	cta	aag	cag	ctg	tat	1170
357	E	C	S	V	R	L	P	L	W	L	L	K	Q	L	Y	371
1171	ctt	ttt	tgg	caa	aat	agt	gga	act	tca	ttt	cca	agc	aat	aga	gaa	1215
372	L	F	W	Q	N	S	G	T	S	F	P	S	N	R	E	386
1216	gcg	ttg	aac	gat	gca	gaa	ata	gct	gca	gct	ctt	caa	gag	gaa	gag	1260
387	A	L	N	D	A	E	I	A	A	A	L	Q	E	E	E	401
1261	gat	gcg	att	gct	tcg	gcc	agt	ttt	aaa	gct	agt	att	cct	att	gga	1305
402	D	A	I	A	S	A	S	F	K	A	S	I	P	I	G	416
1306	aga	cca	gca	tcc	acc	gcc	gtc	ttg	gta	cca	aac	tgg	tcg	cat	ggt	1350
417	R	P	A	S	T	A	V	L	V	P	N	W	S	H	G	431
1351	ggc	aaa	tct	cct	gat	cca	caa	gag	cgg	caa	cat	ggt	ggt	gat	gac	1395
432	G	K	S	P	D	P	Q	E	R	Q	H	G	G	D	D	446
1396	ctg	gag	cag	act	ttg	gct	agg	atg	acc	tcg	gga	ctc	cag	aga	acc	1440
447	L	E	Q	T	L	A	R	M	T	S	G	L	Q	R	T	461
1441	aca	atg	gtt	aaa	cca	gca	aga	ctc	caa	aaa	att	gga	aat	ttt	gct	1485
462	T	M	V	K	P	A	R	L	Q	K	I	G	N	F	A	476
1486	tgg	gcc	tgc	gca	acc	aat	gag	gac	ggg	cca	tcc	aag	tac	cta	agt	1530
477	W	A	C	A	T	N	E	D	G	P	S	K	Y	L	S	491
1531	agg	tgt	tgg	att	ttt	gtc	cgc	caa	cgg	tat	att	tta	tcc	cat	agg	1575
492	R	C	W	I	F	V	R	Q	R	Y	I	L	S	H	R	506
1576	tat	gat	tct	act	gct	aca	cgc	gct	acc	ctt	cat	atc	atg	ttg	aat	1620
507	Y	D	S	T	A	T	R	A	T	L	H	I	M	L	N	521
1621	cct	gaa	gca	aat	agt	gtg	gag	cat	tgt	cgt	aac	tca	cca	gca	acg	1665
522	P	E	A	N	S	V	E	H	C	R	N	S	P	A	T	536
1666	act	tca	gat	acg	gtt	gta	ccc	gca	caa	aaa	ccc	agc	ttt	aag	cgt	1710
537	T	S	D	T	V	V	P	A	Q	K	P	S	F	K	R	551
1711	cgg	ttt	gaa	gca	aac	ctt	cct	gat	gcc	caa	gaa	aaa	gca	cgt	caa	1755
552	R	F	E	A	N	L	P	D	A	Q	E	K	A	R	Q	566
1756	tat	cag	aaa	caa	gct	aat	gag	ttt	gct	gag	aag	aaa	ttt	gca	gaa	1800
567	Y	Q	K	Q	A	N	E	F	A	E	K	K	F	A	E	581
1801	atg	cga	aaa	ggt	gag	aga	tac	ctt	cag	tgc	cgt	aac	ttg	ctg	gca	1845
582	M	R	K	V	E	R	Y	L	Q	C	R	N	L	L	A	596
1846	gcg	gac	tac	ttc	cgc	caa	gtg	gca	cga	gaa	cat	tct	ctt	cgt	gaa	1890
597	A	D	Y	F	R	Q	V	A	R	E	H	S	L	R	E	611
1891	aag	aat	ctt	cgt	aag	cag	gcc	ggt	gat	att	atc	ata	aaa	gca	aat	1935
612	K	N	L	R	K	Q	A	G	D	I	I	I	K	A	N	626
1936	gaa	gat	tct	acc	gta	ctt	gac	ctt	cat	ctt	ctt	agc	cag	aag	gac	1980
627	E	D	S	T	V	L	D	L	H	L	L	S	Q	K	D	641
1981	gct	att	atg	ttg	cta	aaa	gag	cgt	ctt	tcc	gcg	ctt	gat	cgt	ccc	2025
642	A	I	M	L	L	K	E	R	L	S	A	L	D	R	P	656

IMMUNOBLOT DIAGNOSIS OF ANGIOSTRONGYLIASIS

2026	gtt tcc atg agg cat ggt cgg tct agt cag cgt ctc cat gtc att	2070
657	V S M R H G R S S Q R L H V I	671
2071	acg ggt tac ggt aga agt act ggt gga aga tct gtg ata aaa cca	2115
672	T G Y G R S T G G R S V I K P	686
2116	gca gtc gaa ttc tac ctg aaa agg aaa gga tat atc tat tca ttt	2160
687	A V E F Y L K R K G Y I Y S F	701
2161	gca aat atg ggt gaa gtt gtg gtt caa tgc aaa tag cgc att cta	2205
702	A N M G E V V V Q C K *	
2206	tct gtt ctt cga aag ctg att cac aaa tta tac att aga att tgt	2250
2251	gca ggg agt cct aga cac tgt ttg ttt agc aag ata ggt atg aca	2295
2296	agg cct ttc tgt gta ttt ctg agt ctt cac tgc aaa ttt gtg att	2340
2341	tgt tat tgt tct ttg aat aca caa ctc tgt ccc ttt ctt tcg ttg	2385
2386	att ttt gag tgt ttt tga acg tgc ctg ttt att cgt tgt tga ata	2430
2431	gcc tcc cag cat caa aaa ttt atc ctg tga gaa tga ggc ttt ttt	2475
2476	tac ctc agt tta aga gtt ctc gga ttt cgg gtt tgt cga tat caa	2520
2521	tgc act tag ctt tct tct ttt tta tat gta tga gat ttc tct ttg	2565
2566	aac gtg cat att aat cat aag act act gca gat aga tgg tta act	2610
2611	tta gcc aat agg aag atc cgt agt ttt tct ttt act gta gtt aaa	2655
2656	tgt ttc cta tac aca caa ttg tat tta ctt ggg aac act <u>att aaa</u>	2700
2701	atg ttt tgt tat aaa aaa aaa aaa aaa aaa aaa aaa	2736

Fig 2—Nucleotide and deduced amino acid sequence of clone fAC22. The polyadenylation signal sequence (attaaa) is underlined. An asterisk (*) indicates stop codon. The highlighted region represents the amino acids in Smr domain.

Application of recombinant fusion protein for immunoblotting

Western immunoblot analysis employing the purified 81-kDa recombinant fusion protein was used to determine the protein's efficacy in detecting *A. cantonensis* infections using individual sera from 'clean' patients or those harboring various parasitic infections, including angiostrongyliasis (Fig 5). All proven angiostrongyliasis sera (4 cases) and 53/57 (93.5%) clinically-suspected angiostrongyliasis sera reacted with the fusion

protein. In contrast, none of the 31 sera from the uninfected control group exhibited seroreactivity with this fusion protein. However, cross-reactivity of serum antibodies to the 81 kDa protein was detected in a number of cases of other helminth infections including gnathostomiasis (2/12), bancroftian filariasis (3/8), ascariasis (4/6), echinococcosis (3/5), paragonimiasis (1/10) and opisthorchiasis (2/9). The calculated sensitivity, specificity, and positive and negative predictive value was 93.5, 91.5, 79.0 and 97.5%, respectively.

```

Smr_domain-containing_protein_      MVTPSIHEQCWEPTTNLEHIRKCIQNGHHIMVIMRGIPGSGKSYLASDLI
Clone_fAC22                          -----MQQYAFHAVRYCYEYIFV
                                         *                               *

Smr_domain-containing_protein_      SGTNGAVFNTDKYFVQNGVYQFDPTKLDEYHQKNWKEAKDAIQGKIPII
Clone_fAC22                          VEPETTKYTVRECFRRNIHGIEIWKIDSMMQS-----
                                         *           * * *

Smr_domain-containing_protein_      IDNTNIFVTHMKPYINLAVKNLYEYIFVEPETEWKNAKECARNAHSVP
Clone_fAC22                          -----LLDQGRPTLSCLVGGDREIRLVPPLFSEK-----EHDTE
                                         *       *   * * *   *           *

Smr_domain-containing_protein_      EEKIAYMAECFEKVSLSDVIKPTQLRTPV-PLVDINDEDDTYNLLLSKLD
Clone_fAC22                          FHCLKLRSLVLDTSPNRDEILHLKDDDGPSPEVSIADPPELPLYPNAAVD
                                         * *           * * * * *

Smr_domain-containing_protein_      SLPDSELLGKDATDNKKSSEQLISLIPHQIPKNLRTFGCQTSDLIRVLDLS
Clone_fAC22                          --RSSFLLPSVAPTPAAFSLAVDRRSHIRILEVREVATQTNEIVVTLVCA
                                         * *           * * * * *

Smr_domain-containing_protein_      NPSSSVNDEFVCE TVCDAPDFXYKKMKVKATQAGDGNILSDIELLIAFF
Clone_fAC22                          GVYCPFDDVSEGVPHSVEISKELKSQMKDRVVRMENIPQFSELDVLVAVF
                                         *           * * * * *

Smr_domain-containing_protein_      PDEKPSDLSHILEIAGLKNAMTLLEKEMNAHMDICTPVGKNKNIDAESLSQ
Clone_fAC22                          PYEELGNLSHYQMLGLEECIRLFLVELGAYVDWMAQVTEKPFVEELAASE
                                         * *   * * * * * * * * * *

Smr_domain-containing_protein_      TTYWWDKSECEQVDNNIDNNSPAPFVNFELNRPISEELAPCTYMQCCDP
Clone_fAC22                          LSGTLLHAPVPRTD--WERIAEQESMKEYVVVTEPVYEVGSSRSVDYSGNE
                                         *                               * *

Smr_domain-containing_protein_      EPVPSGYCRMQISVDMMEQLTQLFGDAESNTFLKTYVDLP IYLWRQIYFH
Clone_fAC22                          ITVTLG-----VDLLQKISLLFG-EGIIVEEECVRLPLWLLKQLYLF
                                         * *   * *   * * * * * * * *

Smr_domain-containing_protein_      WQG-I STTTTEVAVAVDNAFGSENFDF SALVSSDEELARILQGHELASDE
Clone_fAC22                          WQNSGTSPFSPNREALNDAEIAAALQEEEDA IASASFKASIPIGRPASTAV
                                         **           * * * * *

Smr_domain-containing_protein_      FLENGKHMSIAERLQLSALMKDYSGVDRERIAECFRDNKFSAEATRNTLD
Clone_fAC22                          LVPNWSHGKSPDPQERQHGGDDLEQLTARMTSGLQRTTMVKPARLQKIG
                                         * *           * * *

Smr_domain-containing_protein_      LRVNGSENIQTVP-----
Clone_fAC22                          NFAWACATNEDGPSKYL SRCWIFVRQRYILSHRYDSTATRATLHIMLNPE
                                         * *

Smr_domain-containing_protein_      ANPSRIEYRPNQSGNCSVXAASSYEESVLPDLELAHKEAFELREQA EW
Clone_fAC22                          ANSVEHCRNSPATTSDTVVPAQKPSFKRRFEANLPDAQEKARQYQKQANE
                                         **           * * * * *

Smr_domain-containing_protein_      YDKQKHELLLRAN--NHRDFGAKMHYFAEAQKLGKKAKDCVAELNERLI
Clone_fAC22                          FAEKKFAEMRKVERYLQCRNLLAADYFRQVAREHSLREKNLRKQAGDIII
                                         * * * * *

Smr_domain-containing_protein_      KANTSTLFLDLHYMNVQSALKLLKAKLNAADRPPEFRRGRSRKLLVLTG
Clone_fAC22                          KANEDSTVLDLHLLSQDAIMLLKERLSALDRPVSMSRHRGRSSQRLHVITG
                                         *** * * * * * * * * * * * * * *

Smr_domain-containing_protein_      YGKLSDGQAKIKPAVIQWLEQCGYEYNTSNKGELIVECK
Clone_fAC22                          YGRSTGGRSVIKPAVEFYLRKRGYIYS-FANMGEVVVQCK
                                         ** * * * * * * * * * *
    
```

Fig 3–Pairwise alignment of deduced amino acid sequence of Smr domain-containing protein of *B. malayi* (accession no. XP_001893874) and deduced amino acid sequence of clone fAC22 by ClustalW. The amino acids that are identical to clone fAC22 are indicated by asterisk and the gap are represented by (--).




Fig 4—Expression, purification and immuno-characterization of 81-kDa recombinant fusion protein. (A) SDS-PAGE analysis; lane M, protein marker, lane 1, uninduced whole cell lysate, lane 2, 1 hour induced whole cell lysate, lane 3, 2 hours induced whole cell lysate, lane 4, 3 hours induced whole cell lysate. (B) Ni-NTA column-purified 81-kDa purified recombinant fusion protein stained with Coomassie brilliant blue. (C) Isolated 81 kDa recombinant protein visualized by silver staining. (D) Reactivity of the 81-kDa recombinant fusion protein with pooled sera from *A. cantonensis*-positive patients. (E) 81-kDa protein reactivity with pooled negative sera. Arrow indicates 81-kDa recombinant protein.

DISCUSSION

Native antigens of *Angiostrongylus cantonensis* worms have been shown to be useful in the detection of antibodies associated with angiostrongyliasis (Eamsobhana *et al*, 2001, 2004; Intapan *et al*, 2003). However, although many immunological tests have demonstrated satisfactory to excellent sensitivities, there still remains considerable room for improvement of the detection rates (Maleewong *et al*, 2001; Intapan *et al*, 2003). In addition, labor, cost and requirement of animals to generate native antigens remain barriers to develop large scale and consistent assay tests.

In the present study, a recombinant protein antigen, identified and cloned from cDNA library of female *A. cantonensis* worm was successfully expressed in *E. coli* and

purified as a potential antigenic assay product. The clone fAC22 was identified by immunoscreening of the cDNA expression library and, following sequence analysis, was identified as an 81-kDa Smr domain-containing protein of *A. cantonensis*. Silver staining of the His6-tagged 81-kDa *A. cantonensis* protein eluted as a single band demonstrated high purity of the recombinant protein preparation, thus providing antigenic material for follow-up serological tests.

The antigenicity of this novel fusion protein was evaluated with sera where infection by *A. cantonensis* worms had been proven, and in cases where the infection criteria were less direct. Using Western blot analysis, the 81-kDa protein specifically reacted with serum antibodies from 57 of the 61 (93.5%) angiostrongyliasis cases,




Fig 5—Detection of angiostrongyliasis infection using *A. cantonensis* 81-kDa recombinant fusion protein. (A) Immunoblot reactivity of the recombinant protein with individual sera from patients with proven angiostrongyliasis ($n = 4$), clinically-suspected angiostrongyliasis ($n = 57$) and other parasitic helminth infections ($n = 144$). “NC”, “PC” and “w” indicate pooled negative control, pooled positive control and proven angiostrongyliasis, respectively. “-” and “+” indicate negative and positive result, respectively. (B) Negative 81-kDa protein reactivity with sera from healthy control people ($n = 31$). Immunoblot reactivity with individual sera from patients with proven (C) gnathostomiasis ($n = 12$), (D) trichinellosis ($n = 11$), (E) brugian filariasis ($n = 8$), (F) bancroftian filariasis ($n = 8$), (G) toxocariasis ($n = 10$), (H) dilofilariasis ($n = 1$), (I) strongyloidiasis ($n = 12$), (J) trichuriasis ($n = 10$), (K) hookworm infection ($n = 10$), (L) ascariasis ($n = 6$), (M) capillariasis ($n = 3$), (N) neurocysticercosis ($n = 9$), (O) taeniasis saginata ($n = 9$), (P) hymenolepiasis ($n = 3$), (Q) sparganosis ($n = 2$), (R) echinococcosis ($n = 5$), (S) paragonimiasis heterotremus ($n = 10$), (T) opistorchiasis ($n = 9$), (U) schistosomiasis ($n = 2$), (V) fascioliasis ($n = 2$), and (W) haplorchiasis ($n = 2$).

which included samples where actual worm infections were confirmed. However, in several cases (36) weak reactions were seen including one of those having a proven infection. Assuming that the recombinant protein possesses multiple antigenic epitopes, differences in reaction intensities likely are due to differences in either quantitative or qualitative reactivities between the fusion protein and antibodies present within the sera of presumptive angiostrongyliasis patients. Importantly, no detectable reactions were observed with any of the negative control sera (31 samples).

The specificity of the recombinant protein also was evaluated with serum antibodies from patients with heterologous infections. The 81 kDa antigen did not crossreact with sera of patients infected with 14 different parasitic infections, while sera from other infections (gnathostomiasis, bancroftian filariasis, ascariasis, echinococcosis, paragonimiasis and opisthorchiasis) yielded varying numbers of positive reactions. Such false positives may have resulted from previous or concurrent *A. cantonensis* infection since cross reactions were observed in only 1-3 cases of those diseases. Of particular note, the Smr domain-containing 81-kDa protein was immunogenic to angiostrongyliasis, but was not to brugian filariasis, as evidenced by the fact that the recombinant protein did not react with antibodies from brugian filariasis patients. This result may be due to the poor homology (approximately 24%) in amino acids sequence of the 81-kDa protein to the *B. malayi* homolog, and thus is consistent with the reaction specificity of this fusion protein. A question that remains, however, is whether the observed cross-reactivity with other helminth infections may be due to the presence of *A. cantonensis* Smr-like protein homolog in

these worm species.

Native proteins isolated from *A. cantonensis* worm extracts have been used as potential antigenic targets in immunoblot-type diagnosis of human angiostrongyliasis. A 31-kDa protein demonstrated highest sensitivity (100%) and specificity (100%) (Eamsobhana *et al*, 2004), but specificity was determined by comparing cross-reactivity using sera representing only 6 other parasitic diseases. Nuamtanong (1996), using the same 31 kDa antigen extract, demonstrated 69.3% sensitivity and 82.4% specificity against serum samples representing 13 different parasitic infections. In this case, the 31-kDa extract showed significant cross-reactivity with sera from patients infected with trichinellosis (8/10), trichuriasis (5/10), and opisthorchiasis (8/10). In addition, 29 kDa antigen from adult worm extracts demonstrated low specificity (47.1%), cross-reacting with most other parasitic infections that were tested (Nuamtanong, 1996). A similar low sensitivity (55.6%) was shown for a 29 kDa native protein from young adult female worms (Maleewong *et al*, 2001). More recently Intapan *et al* (2003), using the 29 kDa antigen of young adult worm and the IgG4 antibody isotype of proven angiostrongyliasis sera, reported 75% sensitivity and 95% specificity, and 85.7% positive and 90.4% negative predictive values. It may be concluded that these assay results involving these two antigenic components should be interpreted with some caution due to the apparent variability in sensitivity, specificity, and their positive and negative predictive values. By comparison, the *A. cantonensis* 81 kDa recombinant protein has demonstrated superior sensitivity (93.5%) and specificity (91.5%) in immunoblot analysis in differentiating active and clinically-presumptive *A. cantonensis* infections.

In summary, a novel 81 kDa protein containing a Smr-like domain was identified by immunoscreening of *A. cantonensis* female adult worm cDNA expression library and was purified from heterologous expression system His-tagged recombinant protein. Western immunoblot analysis indicated its suitability as an antigen for serodiagnosis of human angiostrongyliasis due of its high sensitivity, specificity and negative and positive predictive values. This represents the first recombinant *A. cantonensis* antigenic protein to be produced with demonstrated application to the serodiagnosis of human angiostrongyliasis.

ACKNOWLEDGEMENTS

The authors thank staff of the Department of Helminthology, Faculty of Tropical Medicine, Mahidol University, Thailand and the Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, USA, for providing laboratory facilities and assistance in laboratory techniques. We also thank Dr Norman Scholfield for assistance in editing the manuscript. This research was supported by the Commission on Higher Education, Ministry of Education, Thailand.

REFERENCES

- Akao N, Kondo K, Ohyama TA, Chen ER, Sano M. Antigens of adult female worm of *Angiostrongylus cantonensis* recognized by infected humans. *Jpn J Parasitol* 1992; 41: 225-31.
- Chen SN. Enzyme-linked immunosorbent assay (ELISA) for detection of antibodies to *Angiostrongylus cantonensis*. *Trans R Soc Trop Med Hyg* 1986; 80: 398-405.
- Chen XG, Li H, Lun ZR. Angiostrongyliasis, mainland China. *Emerg Infect Dis* 2005; 11: 1645-7.
- Cross JH, Chi JCH. ELISA for the detection of *Angiostrongylus cantonensis* antibodies in patients with eosinophilic meningitis. *Southeast Asian J Trop Med Public Health* 1982; 13: 73-6.
- Eamsobhana P, Mak JW, Yong HS. Detection of circulating antigens of *Parastrongylus cantonensis* in human sera by sandwich ELISA with specific monoclonal antibody. *Southeast Asian J Trop Med Public Health* 1995; 26: 712-5.
- Eamsobhana P, Mark JW, Yong HS. Detection of circulating antigens of *Parastrongylus cantonensis* in human sera by dot-blot ELISA and sandwich ELISA using monoclonal antibody. *Southeast Asian J Trop Med Public Health* 1997; 28(suppl): 139-42.
- Eamsobhana P, Yoolek A, Punthuprapasa P, Suvouttho S. A dot-blot ELISA comparable to immunoblot for the specific diagnosis of human parastrongyliasis. *J Helminthol* 2004; 78: 287-91.
- Eamsobhana P, Yoolek A, Suvouttho S, Suvouttho S. Purification of a specific immunodiagnostic *Parastrongylus cantonensis* antigen by electroelution from SDS-polyacrylamide gels. *Southeast Asian J Trop Med Public Health* 2001; 23: 308-13.
- Galen RS. Predictive value and efficiency of laboratory testing. *Pediatr Clin North Am* 1980; 27: 816-9.
- Garcia LS. Diagnostic medical parasitology. 5th ed. Wahington, DC: ASM Press, 2007.
- Intapan PM, Maleewong W, Sawanyawisuth K, Chotmongkol V. Evaluation of human IgG subclass antibodies in the serodiagnosis of angiostrongyliasis. *Parasitol Res* 2003; 89: 425-9.
- Maleewong W, Sombatsawat P, Intapan PM, Wongkham C, Chotmongkol V. Immunoblot evaluation of the specificity of the 29-kDa antigen from young adult female worms *Angiostrongylus cantonensis* for immunodiagnosis of human angiostrongyliasis. *Asian Pac J Allergy Immunol* 2001; 19: 267-73.

- Nuamtanong S. The evaluation of the 29 and 31 kDa antigens in female *Angiostrongylus cantonensis* for serodiagnosis of human angiostrongyliasis. *Southeast Asian J Trop Med Public Health* 1996; 27: 291-6.
- Sawanyawisuth K, Kitthaweesin K, Limpawattana P, *et al.* Intraocular angiostrongyliasis: clinical finding, treatment and outcome. *Trans R Soc Trop Med Hyg* 2007; 101: 497-501.
- Sinawat S, Sanguansak T, Angkawinijwong T, *et al.* Ocular angiostrongyliasis: clinical study of three cases. *Eye* 2008; 1-3.
- Slom TJ, Cortese MM, Gerber SI, *et al.* An outbreak of eosinophilic meningitis caused by *Angiostrongylus cantonensis* in travelers returning from the Caribbean. *N Engl J Med* 2002; 346: 668-75.
- Tsai HC, Liu YC, Kunin CM, *et al.* Eosinophilic meningitis caused by *Angiostrongylus cantonensis*: report of 17 cases. *Am J Med* 2001; 111: 109-14.
- Wang QP, Lai DH, Zhu XQ, Chen XG, Lun ZR. Human angiostrongyliasis. *Lancet Infect Dis* 2008; 8: 621-30.
- Welch JS, Dobson C, Campbell GR. Immunodiagnosis and seroepidemiology of *Angiostrongylus cantonensis*. *Trans R Soc Trop Med Hyg* 1980; 74:614-23.
- Yen CM, Chen ER. Detection of antibodies to *Angiostrongylus cantonensis* in serum and cerebrospinal fluid of patients with eosinophilic meningitis. *Int J Parasitol* 1991; 21: 17-21.